ABSTRACT
BackgroundThe unprecedented impact of the Covid-19 pandemics on modern society has ignited a "gold rush" for effective treatment and diagnostic strategies, with a significant diversion of economical, scientific and human resources towards dedicated clinical research. We aimed to describe trends in this rapidly changing landscape to inform adequate resource allocation. MethodsWe developed informatic tools (Covid Trial Monitor) to analyze in real time growth rate, geographical distribution and characteristics of Covid-19 related trials. We defined structured semantic ontologies with controlled vocabularies to categorize trial interventions, study endpoints and study designs. Data and analyses are publicly available at https://bioinfo.ieo.it/shiny/app/CovidCT ResultsWe observe a clear prevalence of monocentric trials with highly heterogeneous endpoints and a significant disconnect between geographic distribution and disease prevalence, implying that most countries would need to recruit unrealistic percentages of their total prevalent cases to fulfill enrolment. ConclusionsThis geographically and methodologically incoherent growth sheds doubts on the actual feasibility of locally reaching target sample sizes and the probability of most of these trials providing reliable and transferable result. We call for the harmonization of clinical trial design criteria for Covid19 and the increased use of larger master protocols incorporating elements of adaptive designs. Covid Trial Monitor identifies critical issues in current Covid19-related clinical research and represents a useful resource for researchers and policymakers to improve the quality and efficiency of related trials
